These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15682309)

  • 21. Behavioral effects associated with chronic ketamine or remacemide exposure in rats.
    Wright LK; Pearson EC; Hammond TG; Paule MG
    Neurotoxicol Teratol; 2007; 29(3):348-59. PubMed ID: 17291718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toluene exposure during the brain growth spurt reduces behavioral responses to noncompetitive N-methyl-D-aspartate receptor antagonists in adult rats.
    Chien TH; Chan MH; Tang YC; Chen HH
    Psychopharmacology (Berl); 2005 Nov; 182(4):468-74. PubMed ID: 16136300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comment on "Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D(2) receptor".
    Krystal JH; D'Souza DC
    Biol Psychiatry; 2001 Oct; 50(7):555-6. PubMed ID: 11600110
    [No Abstract]   [Full Text] [Related]  

  • 24. The NMDA antagonist model for schizophrenia: promise and pitfalls.
    Abi-Saab WM; D'Souza DC; Moghaddam B; Krystal JH
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():104-9. PubMed ID: 9754841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the NMDA antagonist ketamine on task-switching performance: evidence for specific impairments of executive control.
    Stoet G; Snyder LH
    Neuropsychopharmacology; 2006 Aug; 31(8):1675-81. PubMed ID: 16205773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
    Malhotra AK; Pinals DA; Weingartner H; Sirocco K; Missar CD; Pickar D; Breier A
    Neuropsychopharmacology; 1996 May; 14(5):301-7. PubMed ID: 8703299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the discriminative stimulus effects of N-methyl- D-aspartate ligands under different ethanol training conditions in the cynomolgus monkey ( Macaca fascicularis).
    Vivian JA; Waters CA; Szeliga KT; Jordan K; Grant KA
    Psychopharmacology (Berl); 2002 Jul; 162(3):273-81. PubMed ID: 12122485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys.
    Sun L; Li Q; Li Q; Zhang Y; Liu D; Jiang H; Pan F; Yew DT
    Addict Biol; 2014 Mar; 19(2):185-94. PubMed ID: 23145560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketamine does not decrease striatal dopamine D2 receptor binding in man.
    Aalto S; Hirvonen J; Kajander J; Scheinin H; Någren K; Vilkman H; Gustafsson L; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 2002 Dec; 164(4):401-6. PubMed ID: 12457270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ketamine attenuates glutamate-induced mechanical sensitization of the masseter muscle in human males.
    Cairns BE; Svensson P; Wang K; Castrillon E; Hupfeld S; Sessle BJ; Arendt-Nielsen L
    Exp Brain Res; 2006 Mar; 169(4):467-72. PubMed ID: 16292641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations of plasma and cerebrospinal fluid glutamate levels in rats treated with the N-methyl-D-aspartate receptor antagonist, ketamine.
    Tomiya M; Fukushima T; Kawai J; Aoyama C; Mitsuhashi S; Santa T; Imai K; Toyo'oka T
    Biomed Chromatogr; 2006; 20(6-7):628-33. PubMed ID: 16779778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and sensorimotor gating effects of ketamine in normals.
    Duncan EJ; Madonick SH; Parwani A; Angrist B; Rajan R; Chakravorty S; Efferen TR; Szilagyi S; Stephanides M; Chappell PB; Gonzenbach S; Ko GN; Rotrosen JP
    Neuropsychopharmacology; 2001 Jul; 25(1):72-83. PubMed ID: 11377920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of ketamine on sexual behavior, anxiety, and locomotion in female rats.
    Guarraci FA; Gonzalez CMF; Lucero D; Womble PD; Abdel-Rahim H; DeVore J; Kunkel MN; Quadlander E; Stinnett M; Boyette-Davis J
    Pharmacol Biochem Behav; 2018 Feb; 165():36-44. PubMed ID: 29273457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phencyclidine supersensitivity in rats with neonatal dopamine loss.
    Moy SS; Breese GR
    Psychopharmacology (Berl); 2002 May; 161(3):255-62. PubMed ID: 12021828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.
    Chizh BA
    J Psychopharmacol; 2007 May; 21(3):259-71. PubMed ID: 17591654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers.
    Hetem LA; Danion JM; Diemunsch P; Brandt C
    Psychopharmacology (Berl); 2000 Oct; 152(3):283-8. PubMed ID: 11105938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.
    Stone JM; Erlandsson K; Arstad E; Squassante L; Teneggi V; Bressan RA; Krystal JH; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2008 Apr; 197(3):401-8. PubMed ID: 18176855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of esketamine in the treatment of negative symptoms in schizophrenia - A case series.
    Nunes MV; Adelino MPM; Ajub E; Quarantini LC; Lacerda ALT
    Schizophr Res; 2018 Dec; 202():394-396. PubMed ID: 29935883
    [No Abstract]   [Full Text] [Related]  

  • 40. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude.
    Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS
    Int J Neuropsychopharmacol; 2009 Jul; 12(6):823-32. PubMed ID: 19154656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.